Gene, Cell, & RNA Therapy Landscape Report

Q3: Tecelra approval + a diversifying field

In Q3 2024:

• Tecelra became the first gene therapy approved for adults with metastatic synovial sarcoma and the first FDA-approved T-cell receptor (TCR) gene therapy

• The field steadily diversified, with data showing 51% of newly initiated gene therapy trials are for non-oncology indications, up from 39% year-over-year

• Seed and Series A funding nearly doubled to $484 million